Novavax, Inc. has issued a clarification regarding an analyst report published on October 1, 2024, which discussed the U.S. market for COVID-19 vaccinations for the upcoming 2024-2025 season. The company stated that while it expects the market to be similar to the previous year, it has not updated or reaffirmed its financial guidance for the full year 2024, which was previously issued on August 8, 2024. Novavax also highlighted the forward-looking nature of statements regarding market expectations, emphasizing that they are based on current beliefs and expectations, not guarantees of future performance. The company outlined various risks and uncertainties that could impact its business, including its partnership with Sanofi Pasteur, Inc., regulatory authorizations, manufacturing and distribution challenges, and market acceptance of its updated COVID-19 vaccine. Novavax's reliance on partners like Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for vaccine production was also noted as a potential risk factor. The company's filings with the SEC contain a more detailed discussion of these risks.

Novavax, Inc. has issued a clarification regarding an analyst report published on October 1, 2024, which discussed the U.S. market for COVID-19 vaccinations for the upcoming 2024-2025 season. The company stated that while it expects the market to be similar to the previous year, it has not updated or reaffirmed its financial guidance for the full year 2024, which was previously issued on August 8, 2024. Novavax also highlighted the forward-looking nature of statements regarding market expectations, emphasizing that they are based on current beliefs and expectations, not guarantees of future performance. The company outlined various risks and uncertainties that could impact its business, including its partnership with Sanofi Pasteur, Inc., regulatory authorizations, manufacturing and distribution challenges, and market acceptance of its updated COVID-19 vaccine. Novavax's reliance on partners like Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for vaccine production was also noted as a potential risk factor. The company's filings with the SEC contain a more detailed discussion of these risks.